AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.

Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb, in a deal that would create one of the world’s largest pharmaceutical groups. The FTSE 100 giant has held talks with the US group in recent months about a possible tie-up, according to reports in the Financial Times.  Talks could lead

The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.

Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.

The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion.

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports  Reuters

Tie-up would create one of the world’s biggest drugmakers